2015: year of the biosimilar

In March 2010, US President Barack Obama signed the Patient Protection and Affordable Care Act, also known as Obamacare, into law. It was preceded in 2009 by the Biologics Price Competition and Innovation Act (BPCIA), which introduced a shortened pathway for approving biosimilars, medicines that have been developed to be close to existing biologic drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Penile implant maker’s $17m trade secret award unravels

20 April 2026 The maker of a cosmetic penile implant has suffered at the Federal Circuit, after a ruling said its trade secrets claims are not protectable while leaving a counterfeiting finding intact.

Americas

Appeals court eases Teva’s headache with reversal

17 April 2026 A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.

Americas

Cancer drug researcher hit with suit over mutation-targeting tools

16 April 2026 The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.